The country of origin of Azelaic Acid Gel, 15% (ANDA 208724)
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- In this case, we find the mixing of the active ingredient, Azelaic Acid (made in Germany) with the inactive ingredients into the final dosage Azelaic Acid Gel in India does not result in a substantial transformation and the country of origin will be Germany.
Ruling text
In your letter dated November 15, 2024, on behalf of Encube Ethicals Private Limited, you requested a country of origin ruling on Azelaic Acid Gel, 15% (ANDA 208724). Azelaic Acid Gel, 15%, imported in 50 grams tubes, is an aqueous gel which contains azelaic acid, a naturally-occurring saturated dicarboxylic acid. It is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
You stated that the active pharmaceutical ingredient (API), Azelaic Acid, is made in Germany, and that the finished gel in dosage form is made in India. In India, the Azelaic Acid will be mixed with various inactive ingredients to produce the final Azelaic Acid Gel in dosage form. Section 134.1(b), Customs Regulations (19 CFR 134.1(b)), defines "country of origin" as: The country of manufacture, production or growth of any article of foreign origin entering the United States.
Further work or material added to an article in another country must effect a substantial transformation in order to render such other country the "country of origin" within the meaning of this part; …. A substantial transformation occurs when an article emerges from a process with a new name, character or use different from that possessed by the article prior to processing. A substantial transformation will not result from a minor manufacturing or combining process that leaves the identity of the article intact.
See United States v. Gibson-Thomsen Co., 27 C.C.P.A. 267 (1940); and National Juice Products Association v. United States, 628 F. Supp. 978 (Ct. Int’l Trade 1986). In this case, we find the mixing of the active ingredient, Azelaic Acid (made in Germany) with the inactive ingredients into the final dosage Azelaic Acid Gel in India does not result in a substantial transformation and the country of origin will be Germany. You also submitted pictures of labels for our review.
Based upon the labels provided, the subject product does not appear to be legally marked with the proper country of origin. The labels state the product is manufactured in India and distributed in the United States. However, the country of origin is Germany where the API is made and should be marked “Made in”,” Product of,” or other words of similar meaning with “Germany” as the country of origin.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov.
The holding set forth above applies only to the specific factual situation and merchandise description as identified in the ruling request. This position is clearly set forth in Title 19, Code of Federal Regulations (CFR), Section 177.9(b)(1).
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N344059).